MarketInOut Stock Screener Log In | Sign Up
 

Mesoblast Ltd ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 09/22/2026 12:52
Mesoblast Ltd ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,964.7 mln
Float94.78 mln
Earnings Date03/04/2027

Piotroski F-Score

1 / 9
Very weak

1-Year Forecast

37.00
Transformational upside

Relative Strength

28 / 100
Underperforming

Debt / Equity

0.22
Very low leverage

Pre-Tax Margin

-46%
Deeply loss-making

ROE

-9.86
Negative

Business Description

Mesoblast is an Australian biotech company founded in 2004 that develops cell-based therapies to treat serious inflammatory and degenerative conditions across multiple countries. Its work centers on a specialized cell technology used to create treatments for conditions such as graft versus host disease, heart failure, inflammatory bowel disease, and chronic back pain. The company has formed partnerships with pharmaceutical firms including Tasly, JCR Pharmaceuticals, and Grünenthal to bring several of these therapies to patients around the world.

Key Fundamentals

EPS-0.44
ROE-9.86
RPS0.93
ROIC-16.74
ROA-4.11
EBITDA, mln-37.01
EV / EBITDA-61.74
EV / EBIT-61.74
Revenue, mln120
EV / Revenue19.00

Quote Details

Last 15.86
Change 0.38 (2.45%)
Open 15.51
Volume 86,944
Turnover 1,378,932
Average Volume 181,480

Financial Ratios

Pre-Tax Profit Margin-46
Leverage Ratio1.36
Current Ratio2.43
Price / Book3.75
Debt / Equity0.22
Price / Sales17.89

Financial Strength

Piotroski F-Score 1 / 9
1-Year Target Price37.00
Short Ratio15.71
Short % of Float3.33

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 7.6% 84 / 100   
1 Month -6.71% 25 / 100   
2 Months 15.26% 86 / 100   
6 Months 13.12% 66 / 100   
1 Year -6.76% 36 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us